TheraJect
TheraJect is a preclinical-stage biopharmaceutical company developing a proprietary microneedle-based transdermal drug delivery platform for painless administration of pharmaceuticals, vaccines, and cosmetic treatments, serving pharmaceutical partners such as JW Pharmaceutical.
- Company typePrivate
- Founded2002
- HeadquartersFremont, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What TheraJect does
TheraJect, Inc. is a preclinical-stage biopharmaceutical company founded in 2002 and headquartered in Fremont, California, with 11-50 employees. The company develops a proprietary microneedle-based transdermal drug delivery platform designed for painless, minimally invasive administration of pharmaceuticals, vaccines, and cosmetic/therapeutic treatments. Its core technology spans multiple application domains — pharmaceutical delivery, vaccination, cosmetics, and diagnostics — and is positioned against conventional hypodermic needle delivery on the basis of patient comfort, compliance, reduced cold-chain burden for vaccines, and potential dose-sparing effects.
The company's go-to-market posture is best characterized as a horizontal platform play targeting pharmaceutical companies that require advanced transdermal delivery solutions; pricing, channel structure, and revenue mechanics are not publicly disclosed. A concrete commercial proof-point is the October 2023 strategic co-development partnership with South Korea-based JW Pharmaceutical Corp., executed through Theraject Asia Co., Ltd., to develop microneedle-based hair loss treatments — the company's most advanced named therapeutic application. To date, the only documented financing is a $500,000 National Science Foundation grant awarded in August 2012; there is no record of dilutive venture funding, revenue, or commercial product sales in the supplied data, and the company's website is currently non-informative (returning only a verification loader), limiting visibility into current operating detail.
Because TheraJect remains preclinical, its near-term value drivers are regulatory pathway (microneedle-plus-antigen combination products face FDA BLA / EMA MAA frameworks) and partnership monetization rather than product revenue. The addressable end-markets are sizable and growing — global microneedle market projected from $1.27B (2024) to $2.18B (2033) at ~6.2% CAGR, the microneedle drug delivery systems market projected to reach $13.16B by 2030 at 17.4% CAGR — but TheraJect's capture of these markets will depend on clinical advancement and licensing outcomes not yet evidenced in the input.
TheraJect firmographics
Firmographics- Name
- TheraJect
- Website
- https://theraject.com
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- TheraJect is a preclinical-stage biopharmaceutical company developing a proprietary microneedle-based transdermal drug delivery platform for painless administration of pharmaceuticals, vaccines, and cosmetic treatments, serving pharmaceutical partners such as JW Pharmaceutical.
- Ownership category
- akta.pro rank
TheraJect industry classification
Industry- Product category
- Transdermal Drug Delivery Systems
- NAICS
- Medical Equipment and Supplies Manufacturing (3391), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral) (HLAAAEAF)
Keywords
Where TheraJect is headquartered
LocationHeadquarters
- HQ city
- Fremont
- HQ country
- United States
- HQ region
- North America
Markets served
TheraJect business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
TheraJect product offering
Product offeringCore offering
TheraJect is a preclinical-stage biopharmaceutical company developing a proprietary microneedle-based transdermal drug delivery platform for painless, minimally invasive administration of pharmaceuticals, vaccines, and cosmetic/therapeutic treatments. The company is applying the platform to specific indications via co-development partnerships, including microneedle-based hair loss treatments with JW Pharmaceutical Corp.
Differentiator
Problem solved
Functional benefit
Products and services
- Microneedle-Based Transdermal Drug Delivery Platform Proprietary platform technology enabling painless, minimally invasive transdermal administration of pharmaceuticals, vaccines, and cosmetic treatments, designed to be licensed or partnered with pharmaceutical and biotechnology companies.
- Microneedle-Based Hair Loss Treatment Therapeutic candidate applying TheraJect's microneedle transdermal delivery technology to hair loss treatment, being co-developed with JW Pharmaceutical Corp. for the dermatology/hair restoration market.
Quantifiable outcome
- Market growth from $1.27B (2024) to $2.18B (2033) at 6.2% CAGR
Companies that use TheraJect
Customer profileSegments1 record
Ideal customer profiles1 record
TheraJect technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
TheraJect partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- JW Pharmaceutical Corp.coreSouth Korea-based JW Pharmaceutical Corp. partnered with Theraject Asia Co., Ltd. in October 2023 to develop microneedle-based hair loss treatments using proprietary transdermal delivery technology. This partnership represents a strategic co-development relationship focused on expanding therapeutic applications of microneedle technology into the dermatology/hair restoration market segment.
Scale indicators5 records
Recent moves2 records
Expansion highlights3 records
TheraJect competitors and assessment
Company assessmentBroad incumbents
- Corium (Gurnet Point): Specialty transdermal drug delivery developer of patch-based products. Overlaps with TheraJect on transdermal delivery mechanism but operates a broader commercial-stage portfolio.
- 3M Drug Delivery Systems: Established contract developer and manufacturer of transdermal drug delivery systems. Comparable microneedle and transdermal capability set but operates at vastly larger scale as part of a diversified industrial conglomerate.
- LTS Lohmann Therapie-Systeme: Global leader in transdermal therapeutic systems and oral thin-film drug delivery. Comparable delivery technology scope relevant to TheraJect's transdermal vaccine/pharma positioning.
- Noven Pharmaceuticals (Hisamitsu): Developer of transdermal drug delivery patches within Hisamitsu Pharmaceutical. Comparable transdermal delivery capability but with a mature, commercial-stage product portfolio.
- Becton Dickinson (BD) Pharmaceutical Systems: Major manufacturer of prefillable drug delivery systems, including self-injection and patch-adjacent devices. Adjacent competitive positioning due to dominance in injectable delivery formats that microneedles aim to displace.
- Halozyme Therapeutics: Developer of drug delivery platforms (ENHANZE) that improve subcutaneous administration of injectable therapeutics. Comparable enabling-delivery-technology business model with established biopharma partnerships.
Direct peers
- Micron Biomedical: Microneedle patch developer for vaccine and therapeutic delivery, including measles-rubella and influenza programs. Directly comparable platform with a strong vaccine focus similar to TheraJect's positioning.
- Zosano Pharma: Clinical-stage developer of microneedle patch-based transdermal drug delivery for therapeutic indications. Closest direct peer to TheraJect's microneedle platform thesis and application space.
- Vaxxas: Developer of high-density microarray patch (microneedle) technology for vaccines and therapeutics. Directly comparable delivery platform with overlapping vaccine and pharmaceutical use cases.
Emerging players
- Dermavant Sciences: Dermatology-focused therapeutics developer with topical/plosive-based delivery. Comparable commercial focus on dermatology — the same indication where TheraJect's JW Pharmaceutical hair-loss partnership is anchored.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
TheraJect social profiles
Digital presenceTheraJect financial estimates
Financial estimateRevenue estimate
Valuation estimate
TheraJect leadership team
Management profileNumber of profiles
Profiles1 record
TheraJect funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TheraJect M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TheraJect
What does TheraJect do?
TheraJect is a preclinical-stage biopharmaceutical company developing a proprietary microneedle-based transdermal drug delivery platform for painless, minimally invasive administration of pharmaceuticals, vaccines, and cosmetic/therapeutic treatments. The company is applying the platform to specific indications via co-development partnerships, including microneedle-based hair loss treatments with JW Pharmaceutical Corp.
Is TheraJect a public or private company?
TheraJect is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was TheraJect founded?
TheraJect was founded in 2002. It employs 11 to 50 people.
Where is TheraJect based?
TheraJect is headquartered in Fremont, United States, in the North America region.
Who are TheraJect's main competitors?
Broad incumbents on record are Corium (Gurnet Point), 3M Drug Delivery Systems, LTS Lohmann Therapie-Systeme, Noven Pharmaceuticals (Hisamitsu), Becton Dickinson (BD) Pharmaceutical Systems and Halozyme Therapeutics. Direct peers are Micron Biomedical, Zosano Pharma and Vaxxas. Dermavant Sciences is listed as an emerging player.
Does TheraJect have an API?
No public API is recorded for TheraJect.
What industry is TheraJect in?
TheraJect's product category is Transdermal Drug Delivery Systems. Its primary akta.pro industry code is HLAAAEAF, Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral). Its NAICS code is 3391 and its SIC code is 3841.